

SPECIAL ARTICLE

Global Kidney Exchange: opportunity or exploitation? An ELPAT/ESOT appraisal

Frederike Ambagtsheer¹ , Bernadette Haase-Kromwijk², Frank J. M. F. Dor^{3,4}, Greg Moorlock⁵, Franco Citterio⁶, Thierry Berney⁷  & Emma K. Massey¹ 

1 Department of Internal Medicine, Nephrology & Transplantation, Erasmus MC, Rotterdam, The Netherlands

2 Dutch Transplant Foundation, Leiden, The Netherlands

3 Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, UK

4 Department of Surgery and Cancer, Imperial College, London, UK

5 Warwick Medical School, University of Warwick, Coventry, UK

6 Renal Transplantation Unit, Fondazione Policlinico Universitario, A. Gemelli, Rome, Italy

7 Division of Transplantation, University of Geneva Hospitals, Geneva, Switzerland

Correspondence

Dr. Frederike Ambagtsheer, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
Tel.: +31 (0) 6 17354137;
e-mail: j.ambagtsheer@erasmusmc.nl

SUMMARY

This paper addresses ethical, legal, and psychosocial aspects of Global Kidney Exchange (GKE). Concerns have been raised that GKE violates the nonpayment principle, exploits donors in low- and middle-income countries, and detracts from the aim of self-sufficiency. We review the arguments for and against GKE. We argue that while some concerns about GKE are justified based on the available evidence, others are speculative and do not apply exclusively to GKE but to living donation more generally. We posit that concerns can be mitigated by implementing safeguards, by developing minimum quality criteria and by establishing an international committee that independently monitors and evaluates GKE's procedures and outcomes. Several questions remain however that warrant further clarification. What are the experiences and views of recipients and donors participating in GKE? Who manages the escrow funds that have been put in place for donor and recipients? What procedures and safeguards have been put in place to prevent corruption of these funds? What are the inclusion criteria for participating GKE centers? GKE provides opportunity to promote access to donation and transplantation but can only be conducted with the appropriate safeguards. Patients' and donors' voices are missing in this debate.

Transplant International 2020;

Key words

chronic kidney disease, kidney transplantation, living donation, medical ethics, organ trafficking

Received: 10 February 2020; Revision requested: 11 March 2020; Accepted: 24 April 2020

Glossary

Alliance for Paired Kidney Donation (APD)
a charitable foundation that aims to establish a universal system that pairs living persons willing to donate a kidney with those needing kidney transplants, in order to increase the number of living donor kidney transplants; improve outcomes for kidney transplant recipients; and significantly reduce public and private costs incurred by chronic kidney disease

Council of Europe (CoE)
an international organization whose aim is to uphold human rights, democracy, and the rule of law in Europe

Council of Europe Committee on Organ Transplantation (CD-P-TO)
the steering committee in charge of organ transplantation activities at the European Directorate for the Quality of Medicines & Healthcare

Council of Europe Convention against Trafficking in Human Organs (CoE Convention)
a treaty that calls on governments to establish the illegal removal of human organs from living or deceased donors as a criminal offense. Legally binding for governments that ratify the convention. Ratified by 9 member states at time of writing

Declaration of Istanbul on Organ Trafficking and Transplant Tourism 2018 Edition (DoI)
statement that defines and prohibits organ trafficking, trafficking in persons for organ removal, and transplant tourism. Calls upon transplant professionals to endorse ethical transplant practices. Not legally binding

Declaration of Istanbul Custodian Group (DICG)
a group of professionals that promotes, implements, and upholds the Declaration of Istanbul so as to combat organ trafficking, transplant tourism, and transplant commercialism and encourages adoption of effective and ethical transplantation practices around the world

European Network for Collaboration on Kidney Exchange Programmes (ENCKEP)
a network supported by European Cooperation in Science and Technology. Brings together policy makers, clinicians, economists, social scientists, and optimization experts in Europe in order to establish and foster a channel for a transnational European kidney exchange program

European Society for Organ Transplantation (ESOT)
the umbrella organization under which transplant activities are structured and streamlined in Europe and worldwide

Ethical, Legal, and Psychosocial Aspects of Transplantation (ELPAT)
European platform that brings continuity and progress in European research and dialogue on Ethical, Legal, and Psychosocial Aspects of organ Transplantation. Section of ESOT

European Union's National Competent Authorities on Organ Donation and Transplantation (NCA)
bodies within the governments of the European Union member states that transpose European Union requirements related to organ donation and transplantation into national law

Global Kidney Exchange (GKE)
an international kidney exchange program that facilitates cross-border exchanges between immunologically incompatible donor–recipient pairs in high-income countries

Kidney exchange programs (KEP)
programs that enable transplantation for recipients who have a willing living donor but are blood and/or HLA incompatible with this donor. These incompatible pairs join a pool of recipient–donor pairs and compatible

matches are made using an algorithm, also referred to as kidney sharing schemes

World Health Organization (WHO)
an international organization that directs international health within the United Nations' system and leads partners in global health responses. Its Guiding Principles on Human Cell, Tissue and Organ Transplantation outline principles that are intended to provide an orderly, ethical and acceptable framework for the procurement and transplantation of human cells, tissues, and organs for therapeutic purposes

Introduction

In 2017, Rees *et al.* [1] introduced “Global Kidney Exchange” (GKE), an international kidney exchange program that facilitates cross-border exchanges between immunologically incompatible donor–recipient pairs in high-income countries (HIC) and biologically compatible but financially impoverished donor–recipient pairs in low- to middle-income countries (LMIC). GKE aims to overcome immunologic barriers in the developed world and poverty barriers in the developing world. The underlying rationale is that financial barriers prevent transplantation much more frequently than organ scarcity. The number of patients dying annually worldwide from end-stage kidney disease due to inadequate financial resources far exceeds the number of patients in developed countries placed on kidney transplantation waitlists [1–3]. GKE has the potential to expand the genetic diversity of the donor pool which may help to transplant difficult-to-transplant, highly immunized patients [1].

In GKE, the health insurance company of the HIC recipient funds both transplants from the costs saved from avoiding or ceasing dialysis. This way, barriers are removed for patients who have a willing living donor but cannot afford the operation or do not have health insurance to cover the costs of donation and transplantation. For national health systems in HIC, global exchange is more cost-effective than continued dialysis. For example, a recent analysis of renal replacement therapy costs in The Netherlands indicates that after a successful transplantation, costs are annually approximately 14–19% of annual dialysis costs [4]. In addition, a new donor–recipient pair in the pool facilitates the transplantation for HIC incompatible pairs and increases the potential to make new chains. At the time of writing, Rees *et al.* have performed 7 GKE exchanges

with The Philippines, Denmark, and Mexico, enabling 36 transplantations [5].

Global Kidney Exchange has received criticism and opposition from the Council of Europe Committee on Organ Transplantation (CD-P-TO), the European Union's National Competent Authorities on Organ Donation and Transplantation (NCA), the Declaration of Istanbul Custodian Group (DICG), and a number of transplant professionals [6-11]. Their concerns are that GKE:

1. violates the principle of nonpayment for organs and constitutes organ trafficking;
2. is exploitative;
3. is coercive;
4. may be undermined by corruption;
5. cannot guarantee proper care for living donors and transplant recipients in LMIC;
6. detracts from countries becoming self-sufficient.

In this paper, we discuss the concerns raised against GKE, but also discuss the potential merits of GKE by providing an overview of ethical, legal, and psychosocial considerations. In doing so, we aim to offer a balanced, evidence-based view of arguments for and against GKE.

Does GKE violate the principle of nonpayment for organs and does it constitute "organ trafficking"?

Global Kidney Exchange provides funding for a kidney transplant procedure (surgery and related medical treatment) to recipients from a LMIC in exchange for a living donor who facilitates a chain of transplants in HIC [1]. According to the DICG, the CD-P-TO, and others, this funding violates the nonpayment principle and constitutes "organ trafficking" [6-9,12]. The principle of nonpayment stipulates that "the human body and its parts shall not give rise to financial gain or comparable advantage" [13,14]. The definition of organ trafficking has been laid down in the 2015 Council of Europe Convention against Trafficking in Human Organs [15] (CoE Convention) and in the 2018 edition of the Declaration of Istanbul on Organ Trafficking and Transplant Tourism (DoI) [16]. According to these instruments, virtually all commercial dealings in organs constitute "organ trafficking" [17,18]. Consequently, whereas organ trafficking was initially only associated with exploiting persons for their organs [19,20], it is now also considered to include the removal of organs for financial gain or comparable advantage [7,9,21].

Rees *et al.* claim that GKE does not violate the nonpayment principle, but that it is consistent with the

altruistic exchanges in kidney exchange programs (KEP) that are accepted practice in many countries. According to them, donors participating in GKE do not "sell" their organ, but "trade" one healthy kidney for another, similar to donors in KEP [1]. The authors further emphasize that GKE removes disincentives for those who would gladly donate a kidney to a friend or family member but cannot due to financial barriers [1].

Removing financial barriers to organ donation is an internationally agreed objective, enshrined, among others, in the World Health Organization's (WHO) Guiding Principles on Human Cell, Tissue and Organ Transplantation and in the CoE Convention [13,15]. These organizations highlight that prohibition of organ payments does not preclude reimbursing expenses incurred by the donor, including the costs of medical procedures [13,17]. Given that countries' legislation vary in their approach to what constitutes illicit payment versus legitimate reimbursement, it is doubtful whether GKE violates the nonpayment principle under all circumstances. For example, the University of Minnesota's legal team vetted GKE and agreed to proceed. Other hospital legal teams have followed suit [1]. However, given the CoE Convention's rather broad definition of "organ trafficking" and the vagueness of the term, "comparable advantage", it is possible that GKE might be considered unlawful in countries that have ratified the CoE Convention [22].¹

Whether GKE is considered illegal is however, in our view, not the most critical issue. The prohibition of payment for organs and organ trafficking has received considerable critique, among others for conflating payments with "trafficking", for failing to eradicate the crime, driving the trade underground and for exposing victims to further harm [20,23-28]. Furthermore, laws are known to follow changing transplant practices [29]. A more relevant question is therefore, whether GKE will help to *induce* or *prevent* organ trafficking. While organizations such as the DICG and CD-P-TO fear that allowing GKE will induce the crime, empirical research suggests that what drives organ trafficking more than scarcity is the global inequity in access to donation and transplantation and the growing divide between the rich and poor [28,30-32]. On the one hand, GKE has the potential to reduce global disparities in access to

¹ As of the beginning of 2020, the CoE Convention has been ratified by Albania, Croatia, Czech Republic, Latvia, Malta, Montenegro, Norway, Portugal and Moldova. For further details, see https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/216/signatures?p_auth=p6Mz9GHQ

donation and transplantation, in particular, to prevent that only the rich patients have access to transplantation [1,33]. On the other hand, this aim can only be achieved if GKE is carried out on a larger scale. Currently, GKE only offers access to transplantation to a select few [1]. If GKE succeeds in reducing disparities in access to donation and transplantation, GKE may contribute to preventing organ trafficking rather than being a constituent of it. If this turns out to be the case, GKE will fulfill the same objectives that the Council of Europe, the DICG and other international bodies have (until now unsuccessfully) been trying to achieve.

Is GKE exploitative?

One criticism of GKE is that it is exploitative, and in order to assess the strength of this claim one must be clear about what one means by exploitation. There is disagreement over where the wrongness of exploitation lies, and it may differ from case to case. It has variously been suggested that exploitation is wrong because it takes advantage of and fails to protect the vulnerable, because it uses people solely as a means to an end, and because it fails to benefit a disadvantaged person in the way that fairness requires [34]. The DICG alludes to some of these aspects when it states that “[e]xploitation occurs when someone takes advantage of a vulnerability in another person for their own benefit, creating a disparity in the benefits gained by the two parties” [9]. It is hard to see, however, that this description of exploitation can be readily applied to GKE. Primarily, it is not clear that there is a significant disparity in benefits between recipients. Each patient receives a kidney transplant, and as Minerva et al point out, benefits are arguably *greater* for LMIC recipients, who get the additional benefit of their follow-up care being paid for [33]. The same is true for the donors, who each obtain the desired benefit of their intended beneficiary receiving a transplant. Rather than there being a morally troubling disparity in benefit, GKE appears to offer either roughly equal benefit, or greater benefit for those who are allegedly exploited.

It is also unconvincing to consider GKE exploitative on other grounds. Rather than failing to protect the vulnerable, it seems that GKE addresses specific vulnerabilities by offering protection to those who are (i) vulnerable to death from kidney failure or (ii) vulnerable to losing a loved one due to kidney failure. It is similarly unconvincing to suggest that GKE treats people merely as a means to an end. Instead, one can see that participants in LMIC are respected as individuals, with

measures put in place to protect their welfare and to ensure that their participation is voluntary.

Another concern raised by Wiseman & Gill, the DICG, and the CD-P-TO is that GKE is not based on humanitarian criteria but instead on the usefulness of the donor from a LMIC for a recipient in a HIC [9,11]. GKE could therefore be considered to be “people in HIC” taking “advantage of a vulnerability in another person for their own benefit”. While this means that the motives of those in HIC may not be purely altruistic, and that the ultimate reason for GKE’s existence may be to provide those in HIC with transplants, it does not make GKE necessarily exploitative. Instead, it emphasizes the importance of careful implementation of GKE: If implemented poorly and with inappropriate safeguards to prevent an unfair disparity in benefits, GKE could become exploitative. If implemented with more caution, however, with stringent safeguards and monitoring to ensure that the rights and welfare of involved parties are protected, GKE can provide a fair distribution of benefits and burdens thereby avoiding a charge of exploitation.

Is GKE coercive?

The claim that donors and recipients in LMIC are too poor or vulnerable to voluntarily engage in GKE is also debatable and could be seen as paternalistic. First of all, the risk that voluntariness is undermined does not apply specifically to GKE or to LMIC alone, but applies to living donation more generally [35]. The argument that a LMIC donor may feel compelled to donate is equally as relevant to the HIC donor candidate: Both are willing but for different reasons cannot help their intended recipient. The potential for pressure to donate is thus present in all KEP. A recent study among professionals demonstrated that safeguarding against coercion is a primary concern during screening in HIC [36]. Furthermore, while costs incurred and loss of wages during the living donation process may deter lower-income donor candidates [37], (low) economic status is not, and should not, be a contraindication for living donation.

Whether or not participants in GKE feel coerced or that they made a voluntary decision requires investigation. This speaks to the need for a qualitative evaluation of views and experiences of those who participate in GKE. Risks arising from potential pressure or coercion can be mitigated by standardized education, psychosocial assessment by mental health professionals, and informed consent procedures that are already in place in countries that have formalized living donation

procedures according to universally recognized standards [38-43].

Will corruption undermine GKE?

Rees *et al.* present a carefully regulated living donation and transplantation program involving a couple from The Philippines, supported by the Alliance for Paired Donation (APD). They reportedly plan to continue the program with transplant centers in Kenya, India, and Ethiopia [6]. APD has created a \$50,000 escrow account to ensure funding for follow-up care for the Filipino donor and recipient. Although Rees *et al.* state that they aim to rule out malpractices, they do not describe how they aim to prevent and alleviate possible corruption of GKE [7,8].

Paradoxically, countries that are most likely to benefit from GKE are those who are the least likely to have safeguards in place to prevent corruption. Research into global financial flows has revealed that more funds leave certain countries than enters them [44,45]. If lump sums resulting from GKE are deposited for donors' and recipients' medical fees upon their return to their country, the questions arise: Who has oversight and access to these funds? How are they audited? How is long-term protection of these funds guaranteed? What are the criteria for using the funds (what can the money be used for and what not)?

Another concern is the inability of some countries to protect transplant recipients and donors from transplant abuses [6,9]. GKE seeks to protect and uphold the rights of individual donors and recipients; however, this is not a certainty in countries where a black market of organ trade exists. An increasing number of studies reveal that some governments have been unable to prevent criminal networks from infiltrating into their transplant centers, turn a blind eye to the practice or wittingly facilitate illegal transplants [28,46-51]. In these countries, exploitation of recipients and donors is most often reported [28,52,53]. In The Philippines, Egypt, Bangladesh, and India, for instance, researchers have repeatedly demonstrated that despite these countries' laws banning organ trafficking, vulnerable individuals continue to sell kidneys, do not receive appropriate pre- and postoperative aftercare and are not recognized or treated as victims [52,54-56]. Only a few successful prosecutions of brokers, recruiters, doctors, and other facilitators of illegal transplants have been reported from both LMIC and HIC [57-59]. The concern therefore arises whether and how governments would address corruption or other violations of GKE if these were to arise.

Rees *et al.* do not explain how they plan to address possible issues of corruption of GKE and exploitation of donors and/or recipients participating in GKE. They may wish to develop criteria that (prospective) collaborating transplant centers need to satisfy. For example, they may wish to include only those centers that have a transparent and long-term track record of successful, legitimate transplantation and donation procedures, including standardized donor screening and follow-up care. All countries participating in GKE, including HIC, should carry equal responsibility to do what is necessary to ensure that patients and donors involved in GKE are adequately protected from the risks associated with corruption, given the need for GKE to avoid venturing into the realms of exploitation.

Can GKE guarantee proper care for living donors and transplant recipients in participating countries?

Another argument against GKE is that participating LMIC are incapable of providing long-term care for transplant recipients and donors [6,9]. This is however not an argument against GKE, but a critique of countries that lack appropriate conditions and safeguards for living donation, registries, and follow-up. It can be argued that countries that are unable to implement basic safeguards for living donation should not be conducting living organ transplants in the first place. It has also been argued that transplant medicine should not come at the expense of primary health care [60]. For this reason, some countries have prohibited transplantation altogether [59].

The claim that these issues only apply to LMIC also warrant careful consideration. First of all, problems with follow-up care of donors and transplant recipients are not exclusively reported from LMIC. Also, HIC struggle to ensure that donors do not get lost to follow-up [61-64]. While the international transplant community agrees upon the necessity of registration of long-term outcomes [64-67], rates of completion are typically low [62,63]. Moreover, even in HIC, low-income recipients experience higher rates of rejection and graft failure than high-income recipients [68-70]. What's more, it is accepted practice in many countries to accept living kidney donors (usually relatives) who travel from abroad [71]. After their donation, these donors typically return to their country of origin, often without guarantee of postoperative and long-term follow-up care. The focus within GKE therefore on low-income patients in LMIC may seem inappropriate when there are also low-

income patients (and donors) in HIC who are in need of improved care. All recipients and donors should be guaranteed proper aftercare, whether or not they participate in GKE.

Ultimately, the concern that GKE lacks the (financial) capacity to guarantee long-term care for donors and recipients may be somewhat overstated. We believe that such issues can be mitigated by APD and/or by an independent committee that monitors and evaluates GKE and that ensures that the escrow funds are not depleted or abused.

Does GKE detract from countries becoming “self-sufficient”?

According to the DICG and NCA, GKE may undermine local efforts to develop transplant programs in both LMIC and HIC. More specifically, they claim that GKE “distracts from efforts to develop sustainable transplant programs within LMICs such as promoting ethical living donation, developing deceased donation, or addressing the financial barriers to immunosuppression” [8,9]. According to these bodies, the fairest and most effective way to address the transplant needs of patients in LMICs is to develop transplant services in their own countries [72].

The proclamation that countries have to be self-sufficient was first declared by the 2008 DoI and the WHO [73,74] and has rapidly gained momentum since [75-77]. The argument to ban GKE because of the need to achieve self-sufficiency raises various implications however. First of all, it implies that the need for countries to become self-sufficient is more important than the lives that can be immediately saved through GKE. Is achievement of self-sufficiency so important that it overrides life-saving alternatives? Who has the authority to decide which approach should get priority? Why is it required that countries become self-sufficient in organ donation and transplantation, while it is universally accepted for countries to rely on global exchanges of all other types of goods and services? Is it realistic to expect that countries will ever achieve self-sufficiency? Given these considerations, it is striking that the proclaimed importance of achieving self-sufficiency receives no criticism and scrutiny from within the transplant community.

Nonetheless, the concern that GKE impedes self-sufficiency is highly speculative. It implies that without GKE, countries are more likely to become self-sufficient. Yet, there is no evidence that supports this assumption. One could also argue that achieving successful kidney

transplantation through GKE could serve as a positive model to boost the status and reputation of transplantation and to promote trust in transplant services across all countries. This may contribute toward achieving self-sufficiency.

Some transplant professionals have pointed out that rather than conducting GKE, countries should focus their efforts on optimizing KEP nationally or regionally.² Only several countries have established national KEP, namely the USA, South Korea, the UK, Australia, The Netherlands, Czech Republic, Austria, and Canada [78]. A number of countries including Greece, Sweden, Switzerland, Poland, and India have been preparing and exploring KEP but have not (yet) implemented a full-running program [79,80]. Most KEP are however not conducted optimally and report a range of problems. Examples include lack of knowledge, small pool sizes, ethical concerns, lack of adequate software, legal barriers, and lack of central coordination [38,79,81]. Some countries such as Romania and Turkey only run single-center KEP. The USA has 3 separate KEP; however, many of its transplant centers are not involved in any of these programs [79]. Rather, numerous regional and single-center programs exist among approximately 250 living donor transplant centers [79]. One of the implications of this fragmented system is that the KEP programs do not wait to build up their pools, as is common practice in other countries with national KEP [79]. Consequently, the success rate of the USA’s KEP is only 10% [79]. The Netherlands, Australia, and the UK by contrast report higher success rates due to leveraged national registries, an oversight body, and frequently run matching cycles [78].

To optimize KEP, the European Network for Collaboration on Kidney Exchange Programmes (ENCKEP) has recommended that countries merge their national pools through regional cooperation [81]. Several countries have started merging their pools with neighboring countries to perform KEP, including Spain, Italy, and Portugal, Denmark, Norway, and Sweden [79,82]. In its forthcoming handbook, ENCKEP presents the criteria that regional KEP should adhere to:

1. countries should experience similar economical and societal development,
2. countries should have comparable ethical and cultural values;

² These statements have been made, for example at the 10th ELPAT Working Group Meeting in Nice, France, in 2018, at the 5th ELPAT Conference in Krakow, Poland, in April 2019, and at the EDTCO conference in November 2018 in Munich, Germany.

3. a robust and sustainable framework with legal certainty for donors, patients, and professionals should be in place;
4. there should be comparable conditions and access to health care for patients [83].

Thus, ENCKEP favors regional KEP over GKE. On the one hand, it can be argued that optimizing KEP within countries and with neighboring countries is a more sustainable solution than engaging in expensive and potentially controversial intercontinental exchanges such as GKE. The high genetic diversity in the USA and Europe, for example, already offers great potential for optimizing national/regional KEP. This in turn is likely to diminish the need for GKE. On the other hand, it can be argued that national/regional KEP, GKE, and other alternatives can co-exist. Multiple strategies that complement one another may result in better all-round results.

GKE: opportunity or exploitation?

In sum, while some concerns about GKE are justified based on the available evidence, others are speculative or do not apply exclusively to GKE but to living donation more generally. We posit that many concerns about GKE can be mitigated by implementing safeguards, by developing minimum quality criteria for participating transplant centers and by establishing an international committee that independently oversees GKE's activities. This committee could be established under the umbrella of an international organization such as the WHO. Its tasks could include the following: screening participating GKE transplant centers, collaborating in defining inclusion criteria for donor–recipients pairs, monitoring adherence to procedures, supervising matching algorithms, overseeing escrow accounts, and evaluating the necessity and suitability of GKE. It could have the authority to visit and inspect transplant centers participating in GKE and provide support and remedies in case of complaints by donors, recipients, and others participating in GKE. Monitoring and evaluating GKE can provide the data necessary to assert – in an evidence-based manner – whether GKE is a safe and successful strategy for improving access to donation and transplantation in both HIC and LMIC. Meanwhile, Rees *et al.* might wish to consider providing clarifications to some remaining questions:

1. What are the perspectives, opinions, and experiences of recipients and donors who have participated in GKE?
2. Who manages the escrow fund(s) that has/have been put in place for donor and recipient pairs? What

safeguards have been put in place to prevent corruption of these funds?

3. What are the inclusion criteria for participating GKE centers? Who initiates the GKE exchanges?
4. What are the inclusion criteria of donor–recipient pairs in both LMIC and HIC?
5. What is the income level of participating donor–recipient pairs?
6. How, where, and by whom is pretransplant assessment and evaluation of donors and recipients conducted? If the donor and recipient travel to a HIC and are found not to be able to proceed, for instance because of a new infection, who pays for the costs incurred by both the healthcare system and the pair thus far? If the reason the transplant cannot proceed is temporary, do the pair remain in the HIC until the transplant can be carried out?
7. How, where, and by whom is post-transplant care and long-term follow-up carried out? For how long is long-term donor and recipient follow-up care guaranteed?
8. What impact does GKE have on transplant activity in participating countries?

Regular updates of GKE case are warranted, including data on follow-up. GKE may provide a much-needed opportunity to promote access to donation and transplantation but must coincide with close monitoring, evaluation, and appropriate safeguards. Patients' and donors' voices are noticeably missing in this debate.

Authorship

FA: wrote the paper, revised drafts, implemented co-authors' comments, approved final version. BH-K: provided comments on drafts, approved final version. FJMFD: provided comments on drafts, approved final version. GM: Warwick, England, provided comments on drafts, co-wrote a paragraph, approved final version. FC: Italy, provided comments on drafts, approved final version. TB: Switzerland, provided comments on drafts, initiated the study, approved final version. EKM: the Netherlands, wrote the paper, revised drafts, implemented comments, approved final version.

Funding

The authors have declared no funding.

Conflicts of interest

The authors have declared no conflicts of interest.

Acknowledgements

The authors are grateful to the ESOT Council and to the anonymous reviewers for their comments on the manuscript.

Authors' statement

The presented arguments reflect the opinions of the authors, not of all ESOT and/or ELPAT members.

REFERENCES

1. Rees MA, Dunn TB, Kuhr CS, et al. Kidney exchange to overcome financial barriers to kidney transplantation. *Am J Transplant* 2017; **17**: 782.
2. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; **382**: 260.
3. White SL, Hirth R, Mahillo B, et al. The global diffusion of organ transplantation: trends, drivers and policy implications. *Bull World Health Organ* 2014; **92**: 826.
4. Mohnen SM, van Oosten MJM, Los J, et al. Healthcare costs of patients on different renal replacement modalities – analysis of Dutch health insurance claims data. *PLoS ONE* 2019; **14**: e0220800.
5. Bozek DN, Ekwenna O, Paloyo S, et al. Global Kidney Exchange. Conference presentation. 2019 American Transplant Congress, 2019. <https://atcmeetingabstracts.com/abstract/global-kidney-exchange-3/> (accessed 14th January 2019).
6. Delmonico FL, Ascher NL. Opposition to irresponsible global kidney exchange. *Am J Transplant* 2017; **17**: 2745.
7. European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO). CD-P-TO position statement on Global Kidney Exchange programmes Strasbourg European Directorate for the Quality of Medicines and Health Care. Council of Europe. Contract No.: PA/PH/TO (18) 3. 2018. https://www.edqm.eu/sites/default/files/statement_cd_p_to_global_kidney_exchange_concept_april_2018.pdf (accessed 31 August 2019).
8. European Union National Competent Authorities on Organ Donation and transplantation. Statement on a proposed concept of global kidney exchange Ref. Ares(2018)2713196 – 25/05/2018, 2018. https://ec.europa.eu/health/sites/health/files/blood_tissues_organ/docs/nca_statement_gke_adopted_en.pdf (accessed 31 August 2019).
9. DICG. Statement of the Declaration of Istanbul Custodian Group concerning ethical objections to the proposed global kidney exchange program, 2018. <http://declarationofistanbul.org/resources/policy-documents/795-statement-of-the-declaration-of-istanbul-custodian-group-concerning-ethical-objections-to-the-proposed-globalkidney-exchange-program> (accessed 16th January 2019).
10. Pullen LC. Global kidney exchange: overcoming the barrier of poverty. *Am J Transplant* 2017; **17**: 2499.
11. Wiseman AC, Gill JS. Financial incompatibility and paired kidney exchange: walking a tightrope or blazing a trail? *Am J Transplant* 2017; **17**: 597.
12. Wiseman AC. Removing financial disincentives to organ donation: an acceptable next step? *Clin J Am Soc Nephrol* 2012; **7**: 1917.
13. WHO. World Health Organization Guiding Principles on Human Cell, Tissue and Organ Transplantation, as endorsed by the sixty-third World Health Assembly in May 2010, in Resolution WHA63.22, 2010. www.who.int (accessed 1 August 2019).
14. Council of Europe. Guide for the implementation of the principle of prohibition of financial gain with respect to the human body and its parts from living or deceased donors, 2018. <https://rm.coe.int/guide-ginancia-l-gain/16807bfc9a> (accessed 29th January 2020).
15. Council of Europe Convention against Trafficking in Human Organs 25.III.2015, 2015. <https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/216> (accessed 24th July 2019).
16. The Declaration of Istanbul. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 Edition). http://www.declarationofistanbul.org/images/Policy_Documents/2018_Ed_Do/2018_Edition_of_the_Declaration_of_Istanbul_Final.pdf (accessed 30th August 2019).
17. Council of Europe. Explanatory Report to the Council of Europe Convention against Trafficking in Human Organs. Santiago de Compostela: Council of Europe 2015. <https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=09000016800d3840> (accessed 6th January 2020).
18. Martin DE, Van Assche K, Domínguez-Gil B, et al. A new edition of the Declaration of Istanbul: updated guidance to combat organ trafficking and transplant tourism worldwide. *Kidney Int.* 2019; **95**: 757.
19. United Nations Office on Drugs and Crime. *United Nations Protocol to Prevent, Suppress and Punish Trafficking in Persons, Especially Women and Children, Supplementing the United Nations Convention Against Transnational Organized Crime*. Vienna: United Nations Office on Drugs and Crime, 2000. Treaty Series, vol. 2237. Sect. A/55/383. <https://www.unodc.org/unodc/treaties/CTOC/>.
20. Columb S, Ambagtsheer F, Bos M, Ivanovski N, Moorlock G, Weimar W. Re-conceptualizing the organ trade: separating “trafficking” from “trade” and the implications for law and policy. *Transpl Int* 2017; **30**: 209.
21. Council of Europe. Handbook for Parliamentarians. The Council of Europe Convention against Trafficking in Human Organs (CETS No. 216), 2019. <https://edoc.coe.int/en/parliamentary-assembly/7992-handbook-for-parliamentarians-the-council-of-europe-convention-against-trafficking-in-human-organs-cets-no-216.html#> (accessed 23rd December 2019).
22. Council of Europe. Chart of signatures and ratifications of Treaty 216. Council of Europe Convention against Trafficking in Human Organ. Status as of 18/11/2019 2019. Available from: https://www.coe.int/en/web/conventions/full-list/-/conventions/treaty/216/signatures?p_auth=bSmdXTu4 (accessed 25th January 2019).
23. Radcliffe Richards J. *The Ethics of Transplants. Why Careless Thought Costs Lives*. Oxford: Oxford University Press, 2012.

24. Price D. Exploitation, Akrasia, and Goldilocks: how many pounds for flesh for medical uses? *Med Law Rev* 2013; **21**: 519.
25. Erin CA, Harris J. A monopsonistic market: or how to buy and sell human organs, tissues and cells ethically. In: Robinson I, ed. *Life and Death Under High Technology Medicine*. New York, NY: Manchester University Press, 1994: 134–156.
26. Rothman DJ, Rose E, Awaya T, et al. The bellagio task force report on transplantation, bodily integrity, and the international traffic in organs. *Transplant Proc* 1997; **29**: 2739.
27. Matas AJ, Satel S, Munn S, et al. Incentives for organ donation: proposed standards for an internationally acceptable system. *Am J Transplant* 2012; **12**: 306.
28. Columb S. Excavating the organ trade: an empirical study of organ trading networks in Cairo, Egypt. *Br J Criminol* 2017; **57**: 1301.
29. Ambagtsheer FaW W. Ethical and legal aspects of kidney donation. In: Knechtle SJ, Marson LP, Morris PJ, eds. *Kidney Transplantation Principles and Practice*, 8th edn. Philadelphia, PA: Elsevier, 2019: 724–736.
30. Yousaf FN, Purkayastha B. 'I am only half alive': organ trafficking in Pakistan amid interlocking oppressions. *Int Sociol* 2015; **30**: 637.
31. Cronin AJ, Johnson RJ, Birch R, Lechler RI, Randhawa G. Solving the kidney transplant crisis for minority ethnic groups in the UK: is being transplanted overseas the answer? In: Weimar W, Bos MA, Busschbach JJ, eds. *Organ Transplantation: Ethical, Legal and Psychosocial Aspects Expanding the European Platform*. Lengerich: Pabst Science Publishers, 2011: 62–72.
32. Moniruzzaman M. "The Heavier Selves": embodied and subjective suffering of organ sellers in Bangladesh. *Ethos* 2019; **47**: 233.
33. Minerva F, Savulescu J, Singer P. The ethics of the Global Kidney Exchange programme. *Lancet* 2019; **394**: 1775.
34. Mayer R. What's wrong with exploitation? *J Appl Philos* 2007; **24**: 137.
35. Hilhorst MT, Van Dijk G. Financial incentives for organ donation. An investigation of the ethical issues. The Hague Centre for Ethics and Health, 2007. <http://hottproject.com/userfiles/Publicaties/FinancialIncentivesVanDijkHilhorst.pdf> (accessed 30th May 2018).
36. Ralph AF, Butow P, Craig JC, et al. Clinicians' attitudes and approaches to evaluating the potential living kidney donor-recipient relationship: an interview study. *Nephrology* 2019; **24**: 252.
37. Rodrigue JR, Schold JD, Morrissey P, et al. Direct and indirect costs following living kidney donation: findings from the KDOC study. *Am J Transplant* 2016; **16**: 869.
38. Lopp L. *Regulations Regarding Living Organ Donation in Europe. Possibilities of Harmonisation*. Munster: University of Munster, 2013.
39. Iacoviello BM, Shenoy A, Braoude J, et al. The live donor assessment tool: a psychosocial assessment tool for live organ donors. *Psychosomatics* 2015; **56**: 254.
40. Massey EK, Timmerman L, Ismail SY, et al. The ELPAT living organ donor Psychosocial Assessment Tool (EPAT): from 'what' to 'how' of psychosocial screening – a pilot study. *Transpl Int* 2018; **31**: 56.
41. Kortram K, Lafranca JA, Ijzermans JNM, Dor FJMF. The need for a standardized informed consent procedure in live donor nephrectomy: a systematic review. *Transplantation* 2014; **98**: 1134.
42. Barr ML, Belghiti J, Villamil FG, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. *Transplantation* 2006; **81**: 1373.
43. The Ethics Committee of the Transplantation Society. The consensus statement of the Amsterdam forum on the care of the live kidney donor. *Transplantation* 2004; **78**: 491.
44. Global Financial Integrity. *Financial Flows and Tax Havens. Combining to Limit the Lives of Billions of People*. Washington: Global Financial Integrity, 2015. https://www.gfintegrity.org/wp-content/uploads/2016/12/Financial_Flows-final.pdf (accessed 17th January 2019).
45. Hickel J. Aid in reverse: how poor countries develop rich countries. The Guardian, 2017. <https://www.theguardian.com/global-development-professionals-network/2017/jan/14/aid-in-reverse-how-poor-countries-develop-rich-countries> (accessed 17th January 2019).
46. Anders W. Is Costa Rica at the Epicenter of a Global Black Market in Human Organs? The Costa Rica Star, 2017. <https://newscocr/is-costa-rica-at-the-epicenter-of-a-global-black-market-in-human-organs/66006/> (accessed 17th January 2019).
47. Mendoza RL. Colombia's organ trade: evidence from Bogota and Medellin. *J Public Health* 2010; **18**: 375.
48. Ambagtsheer F. OrganTrade. Erasmus University Rotterdam 2017 retrieved from www.hottproject.com (accessed 4th July 2019).
49. Moniruzzaman M. The trade in human liver lobes: bioviolence against organ sellers in Bangladesh. *J Roy Anthropol Inst* 2019; **25**: 566.
50. Yousaf FN, Purkayastha B. Social world of organ transplantation, trafficking, and policies. *J Public Health Policy* 2016; **37**: 190.
51. Ambagtsheer F. Combating human trafficking for the purpose of organ removal: lessons learned from prosecuting criminal cases. In: Winterdyk JA, Jones J, eds. *The Palgrave International Handbook of Human Trafficking*. Cham, Switzerland: Palgrave Macmillan, 2019: 1733–1749 pp.
52. Yea S. Masculinity under the knife: Filipino men, trafficking and the black organ market in Manila, the Philippines. *Gender Place Cult* 2015; **22**: 123.
53. De Jong J. Human trafficking for the purpose of organ removal. Utrecht University 2017, retrieved at www.hottproject.com (accessed 4th January 2020).
54. Padilla BS. Regulated compensation for kidney donors in the Philippines. *Curr Opin Organ Transplant* 2009; **14**: 120.
55. Yea S. Trafficking in part(s): the commercial kidney market in a Manila slum, Philippines. *Glob Soc Policy* 2010; **10**: 358.
56. Budiani-Saberi DA, Raja KR, Findley KC, Kerketta P, Anand V. Human trafficking for organ removal in India: a victim-centered, evidence-based report. *Transplantation* 2014; **97**: 380.
57. Case Law Database. United Nations Office on Drugs and Crime. Available from: <http://www.unodc.org/cld/index-sherloc-cld.jsp> (accessed 14th February, 2020).
58. OSCE. *Trafficking in Human Beings for the Purpose of Organ Removal in the OSCE Region: Analysis and Findings*. Vienna: Office of the Special Representative and Co-ordinator for Combating Trafficking in Human Beings. Organization for Security and Co-operation in Europe, 2013. Available from <https://www.osce.org/secretariat/103393> (accessed 6th April 2020).
59. Ambagtsheer F, Weimar W, eds. *Trafficking in Human Beings for the Purpose of Organ Removal: Results and Recommendations*. Lengerich: Pabst Science Publishers, 2016.
60. Columb S. Beneath the organ trade: a critical analysis of the organ trafficking

- discourse. *Crime Law Soc Chang* 2015; **63**: 21.
61. Rodrigue JR, Fleishman A, Sokas CM, et al. Rates of living kidney donor follow-up: findings from the KDOC study. *Transplantation* 2019; **103**: e209.
 62. Schold JD, Buccini LD, Rodrigue JR, et al. Critical factors associated with missing follow-up data for living kidney donors in the United States. *Am J Transplant* 2015; **15**: 2394.
 63. Henderson ML, Thomas AG, Shaffer A, et al. The national landscape of living kidney donor follow-up in the United States. *Am J Transplant* 2017; **17**: 3131.
 64. Lennerling A, Lovén C, Dor FJMF, et al. Living organ donation practices in Europe – results from an online survey. *Transpl Int* 2013; **26**: 145.
 65. Council of Europe Resolution CM/Res (2013)55 on establishing procedures for the collection and dissemination of data on transplantation activities outside a domestic transplantation system, 2013. Available at <https://wcd.oe.int/ViewDoc.jsp?id=2141341&Site=CM> (accessed 3rd May 2019).
 66. British Transplantation Society. Guidelines for Living Donor Kidney Transplantation. Fourth Edition 2018. https://bts.org.uk/wp-content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf (accessed 6th April 2020).
 67. Van Assche K, Sterckx S, Lennerling A, et al. The relevance of directive 2010/53/EU for living organ donation practice: an ELPAT view. *Transplantation* 2015; **99**: 2215.
 68. DuBay DA, MacLennan PA, Reed RD, et al. Insurance type and solid organ transplantation outcomes: a historical perspective on how medicaid expansion might impact transplantation outcomes. *J Am Coll Surg* 2016; **223**: 611.
 69. Begaj I, Khosla S, Ray D, Sharif A. Socioeconomic deprivation is independently associated with mortality post kidney transplantation. *Kidney Int* 2013; **84**: 803.
 70. Wu DA, Robb ML, Watson CJE, et al. Barriers to living donor kidney transplantation in the United Kingdom: a national observational study. *Nephrol Dial Transplant* 2017; **32**: 890.
 71. Shukhman E, Hunt J, LaPointe-Rudow D, et al. Evaluation and care of international living kidney donor candidates: strategies for addressing common considerations and challenges. *Clin Transplant* 2020; **34**: e13792.
 72. Kute V, Jindal RM, Prasad N. Kidney paired-donation program versus global kidney exchange in India. *Am J Transplant* 2017; **17**: 2740.
 73. World Health Organization. Madrid resolution on organ donation and transplantation. *Transplantation* 2011; **91**(Suppl. 11): S29.
 74. The Declaration of Istanbul on Organ Trafficking and Transplant Tourism. Participants in the international summit on transplant tourism organ trafficking convened by the transplantation society international society of nephrology. *Clin J Am Soc Nephrol* 2008; **3**: 1227.
 75. Delmonico FL, Domínguez-Gil B, Matesanz R, Noel L. A call for government accountability to achieve national self-sufficiency in organ donation and transplantation. *Lancet* 2011; **378**: 1414.
 76. Garcia-Garcia G, Harden P, Chapman J. The global role of kidney transplantation. *Nephrology* 2012; **17**: 199.
 77. Jha V. Towards achieving national self-sufficiency in organ donation in India – a call to action. *Indian J Nephrol* 2014; **24**: 271.
 78. Ferrari P, Weimar W, Johnson RJ, Lim WH, Tinckam KJ. Kidney paired donation: principles, protocols and programs. *Nephrol Dial Transplant* 2014; **30**: 1276.
 79. Biró P, Haase-Kromwijk B, Andersson T, et al. Building kidney exchange programmes in Europe – an overview of exchange practice and activities. *Transplantation* 2019; **103**: 1514.
 80. Kute VB, Patel HV, Shah PR, et al. International kidney paired donation transplantations to increase kidney transplant of O group and highly sensitized patient: first report from India. *World J Transplant* 2017; **7**: 64.
 81. ENCKEP. European Network for Collaboration on Kidney Exchange Programmes. Kidney Exchange Practices in Europe. First Handbook of the COST Action CA15210: 2017. European Cooperation in Science & Technology (COST). <http://www.enckep-cost.eu/news/news-first-handbook-of-the-cost-action-ca15210-57> (accessed 3rd December 2019).
 82. Böhmig GA, Fronck J, Slavcev A, Fischer GF, Berlakovich G, Viklicky O. Czech-Austrian kidney paired donation: first European cross-border living donor kidney exchange. *Transpl Int* 2017; **30**: 638.
 83. ENCKEP. European Network for Collaboration on Kidney Exchange Programmes. Kidney Exchange Practices in Europe. Second Handbook of the COST Action: European Cooperation in Science & Technology, forthcoming at <http://www.enckep-cost.eu/>.